Form 10-Q Valeant Pharmaceuticals For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
Go back to Form 10-Q Valeant Pharmaceuticals For: Mar 31
June 8, 2016 7:07 AM EDT
RBC Capital analyst Douglas Miehm lowered estimate and his price target on Sector Perform-rated Valeant Pharmaceuticals (NYSE: VRX) to $33.00 (from $58.00) following mixed earnings, which were overshadowed by sharply lower guidance.
Miehm commented, "Total revenue guidance was lowered to $9.9-10.1B, from $11.0-11.2B and cash EPS guidance... More
June 8, 2016 6:57 AM EDT
Guggenheim analyst, Louise Chen, defended Valeant Pharmaceuticals (NYSE: VRX) as she continues to believe that VRX's long-term growth prospects are underappreciated. Upside to expectations could come from: 1) divestment of non-core products to pay down debt; 2) meeting or beating quarterly earnings in '16; and, 3)... More
June 8, 2016 6:27 AM EDT
BMO Capital analyst Alex Arfaei reiterated a Market Perform rating and cut his price target on Valeant Pharmaceuticals (NYSE: VRX) to $38.00 (from $44.00) after the company cut guidance. While the firm expected the cut, it was greater than they and the market expected.
Arfaei commented, "Although we expected Valeant to lower its guidance, the magnitude of the downward revision was greater than we and the market expected. This... More
June 7, 2016 5:19 PM EDT
Valeant Pharma (NYSE: VRX) filed its form 10-Q with the SEC. The long-awaited filing allows the company to avoid default.
...
More
